Devices Radiology Oncology

 News Release - February 28, 2008

iCAD Introduces Next-Generation TotalLook Film Digitizer

TotalLook MammoAdvantage(TM)Provides Enhanced Image Quality, Customization and Workflow Benefits to Mammography Centers

NASHUA, N.H., Feb. 28 (HSMN NewsFeed) -- iCAD, Inc. (Nasdaq: ICAD ), an industry-leading provider of computer-aided detection (CAD) solutions for the early detection of cancer, today announced the availability of the TotalLook MammoAdvantage system which converts prior mammography films to digital images for comparative review on a single digital review workstation. This new version of iCAD's state-of-the-art film digitizing solution offers improved image quality, enhanced image customization options and workflow efficiency features.

TotalLook MammoAdvantage's new DigitalLook and PremiumLook image outputs closely match digital mammography images offering enhanced tissue visualization, higher contrast and better edge definition to improve comparative reading. TotalLook MammoAdvantage's unique software offers configurable image resolution settings that display the digitized images at the same resolution as the digital mammography images, enabling the digitized and newly acquired digital images to be displayed at the same size. The software provides flexible DICOM connectivity solutions for seamless integration with leading review workstations, PACS and RIS systems.

"TotalLook MammoAdvantage provides radiologists with excellent digitized image quality," said Ken Ferry, Chief Executive Officer of iCAD, Inc. "In addition, the new system enables the most efficient comparative reading of current and prior mammograms, optimizing workflow in all care settings."

About iCAD, Inc.

iCAD, Inc. (Nasdaq: ICAD ) is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over 1800 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.

For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at ddeptula@icadmed.com

For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at icad@lhai.com

For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

Source: iCAD

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.